Potential Therapeutic Targets in Uterine Sarcomas

Table 1

Overview of potential therapeutic targets and corresponding treatments in uterine sarcomas.

	Therapeutic target	Targeted agents
uLMS	HER-2	HER-2 inhibitors (e.g., trastuzumab, CP-724714, CUDC-101)
	EGFR	EGFR inhibitors (e.g., gefitinib, erlotinib, cetuximab, vandetanib)
	PDGFR	PDGFR inhibitors (e.g., pazopanib, imatinib, sunitinib, sorafenib)
	VEGF-VEGFR	VEGF-VEGFR inhibitors (e.g., bevacizumab, aflibercept, vandetanib, cediranib)
	IGF1R	Figitumumab, cixutumumab, AVE1642
	BDNF-NTRK2	BDNF-NTRK2 inhibitors (e.g., K252a)
	PIK3/AKT/mTOR; Loss of PTEN	PIK3/AKT/mTOR pathway inhibitors (e.g., curcumin, rapamycin, ridaforolimus)
	AURKA	AURKA inhibitors (e.g., MLN8237, MK-5108, VE465)
	Wnt/β-catenin	β-catenin inhibitors (e.g., LGK-974, PKF118-310, PNU-74654)
	ROR2	ROR2 inhibitors (not yet developed)
	Endoglin/CD105	Anti-CD105 antibodies (in development)
	MDM2	MDM2 inhibitors (e.g., AMG232, RG7112)
	HDAC	HDAC inhibitors (e.g., vorinostat, valproate)
	CD47	Anti-CD47 antibodies (in development)
	ER, PR	Aromatase inhibitors (e.g., letrozole, exemestane); Progestins (e.g., medroxyprogesterone acetate, megestrol acetate)
	Loss of TSG	Synthetic lethality principle (e.g., PARP inhibitors)
LGESS	PDGFR	PDGFR inhibitors (e.g., pazopanib, imatinib, sunitinib, sorafenib)
	EGFR	EGFR inhibitors (e.g., gefitinib, erlotinib, cetuximab, vandetanib)
	VEGF-VEGFR	VEGF-VEGFR inhibitors (e.g., bevacizumab, aflibercept, vandetanib, cediranib)
	HDAC	HDAC inhibitors (e.g., vorinostat, valproate)
	Wnt/β-catenin	β-catenin inhibitors (e.g. LGK-974, PKF118-310, PNU-74654)
	ER, PR	Aromatase inhibitors (e.g., letrozole); Progestins (e.g., medroxyprogesterone acetate, megestrol acetate)
HGESS	14-3-3 oncoprotein	14-3-3 oncoprotein inhibitors (not yet developed)
	PDGFR	PDGFR inhibitors (e.g., pazopanib, imatinib, sunitinib, sorafenib)
	HER-2	HER-2 inhibitors (e.g., trastuzumab, CP-724714, CUDC-101)
	EGFR	EGFR inhibitors (e.g., gefitinib, erlotinib, cetuximab, vandetanib)
	c-KIT	c-KIT inhibitors (e.g., imatinib, pazopanib)
HGESS/UUS	Tyrosine kinases	Cabozantinib